↓ Skip to main content

Cochrane Database of Systematic Reviews

Ketamine as an adjuvant to opioids for cancer pain

Overview of attention for article published in this source, November 2012
Altmetric Badge

Mentioned by

1 blog
35 X users
2 Facebook pages
1 research highlight platform


96 Dimensions

Readers on

70 Mendeley
1 CiteULike
Ketamine as an adjuvant to opioids for cancer pain
Published by
John Wiley & Sons, Ltd, November 2012
DOI 10.1002/14651858.cd003351.pub2
Pubmed ID

Bell, Rae F, Eccleston, Christopher, Kalso, Eija A


This is an update of the original review published in Issue 1, 2003. Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective. Ketamine is known to have psychotomimetic (including hallucinogenic), urological and hepatic adverse effects.

X Demographics

X Demographics

The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 1%
Australia 1 1%
Unknown 68 97%

Demographic breakdown

Readers by professional status Count As %
Other 11 16%
Student > Master 10 14%
Student > Ph. D. Student 9 13%
Researcher 8 11%
Student > Postgraduate 6 9%
Other 18 26%
Unknown 8 11%
Readers by discipline Count As %
Medicine and Dentistry 39 56%
Psychology 5 7%
Nursing and Health Professions 4 6%
Agricultural and Biological Sciences 4 6%
Social Sciences 2 3%
Other 7 10%
Unknown 9 13%